Market Dynamics 6.1 Growth Driver 6.1.1 Rising Cases of Diabetes 6.1.2 Rising Cases of Obesity 6.1.3 Rapid Urbanization 6.1.4 Increasing Healthcare Expenditure 6.1.5 Increasing Aging Population 6.2 Challenges 6.2.1 Short Half-Life of Glucagon-like Peptide 1 (GLP-1) Receptor Agonists 6.2.2 Unknown Severe Side Effects 6.3 Market Trends 6.3.1 Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH 6.3.2 Surge in Research & Development in Pharmaceutical Sector 6.3.3 New Product Launches 6.3.4 Expanding Reimbursement Landscape 7
The panels recommendations do not mean that the FDA has approved the six peptides, nor does it make these drugs immediately available through compounding pharmacies
Furthermore, these medications contribute to improved metabolic health and may lower the risk of cardiovascular diseases
The Trump administration also reached deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and direct-to-consumer purchases through TrumpRx
CJC-1295 + DAC 5mg CJC-1295+DAC is one of modified synthetic analogues of growth hormone releasing hormone (GHRH)
I always say that if you want to starve to death, open up a bookstore in Miami